387 related articles for article (PubMed ID: 26313461)
21. Clinicopathologic characteristics and survival of male breast cancer.
Liu D; Xie G; Chen M
Int J Clin Oncol; 2014 Apr; 19(2):280-7. PubMed ID: 23640121
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.
Nilsson C; Johansson I; Ahlin C; Thorstenson S; Amini RM; Holmqvist M; Bergkvist L; Hedenfalk I; Fjällskog ML
Acta Oncol; 2013 Jan; 52(1):102-9. PubMed ID: 22928693
[TBL] [Abstract][Full Text] [Related]
23. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
24. Survival Comparisons Between Early Male and Female Breast Cancer Patients.
Wang K; Wang QJ; Xiong YF; Shi Y; Yang WJ; Zhang X; Li HY
Sci Rep; 2018 Jun; 8(1):8900. PubMed ID: 29891971
[TBL] [Abstract][Full Text] [Related]
25. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
26. Male Breast Cancer Prognostic Factors Versus Female Counterparts with Propensity Scores and Matched-Pair Analysis.
Yu E; Stitt L; Vujovic O; Joseph K; Assouline A; Younus J; Perera F; Tai P
Cureus; 2015 Oct; 7(10):e355. PubMed ID: 26623210
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.
Masci G; Caruso M; Caruso F; Salvini P; Carnaghi C; Giordano L; Miserocchi V; Losurdo A; Zuradelli M; Torrisi R; Di Tommaso L; Tinterri C; Testori A; Garcia-Etienne CA; Gatzemeier W; Santoro A
Oncologist; 2015 Jun; 20(6):586-92. PubMed ID: 25948676
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
29. Comparison between male and female breast cancer survival using propensity score matching analysis.
Scomersi S; Giudici F; Cacciatore G; Losurdo P; Fracon S; Cortinovis S; Ceccherini R; Zanconati F; Tonutti M; Bortul M
Sci Rep; 2021 Jun; 11(1):11639. PubMed ID: 34079019
[TBL] [Abstract][Full Text] [Related]
30. Hormone receptor-positive breast cancer and black race: does sex matter?
Eskander MF; Li Y; Bhattacharyya O; Tsung A; Oppong BA; Hamad A; Gatti-Mays M; Obeng-Gyasi S
Breast Cancer Res Treat; 2021 Nov; 190(1):111-119. PubMed ID: 34383180
[TBL] [Abstract][Full Text] [Related]
31. Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry.
Lee EG; Jung SY; Lim MC; Lim J; Kang HS; Lee S; Han JH; Jo H; Won YJ; Lee ES
Cancer Res Treat; 2020 Jul; 52(3):739-746. PubMed ID: 32054149
[TBL] [Abstract][Full Text] [Related]
32. Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study.
Chen W; Huang Y; Lewis GD; Szeja SS; Hatch SS; Farach A; Miltenburg D; Butler EB; Chang JC; Teh BS
Clin Breast Cancer; 2018 Feb; 18(1):e97-e105. PubMed ID: 28888581
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of mitotic index and Bcl2 expression in male breast cancer.
Lacle MM; van der Pol C; Witkamp A; van der Wall E; van Diest PJ
PLoS One; 2013; 8(4):e60138. PubMed ID: 23573235
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
36. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
[TBL] [Abstract][Full Text] [Related]
37. [Clinical features and risk factors for recurrence in mucinous breast cancer].
Lei L; Chen ZZ; Zheng YB; Chen B; Wang X; Wang XJ
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):274-279. PubMed ID: 28550667
[No Abstract] [Full Text] [Related]
38. Tracing differences between male and female breast cancer: both diseases own a different biology.
Kornegoor R; van Diest PJ; Buerger H; Korsching E
Histopathology; 2015 Dec; 67(6):888-97. PubMed ID: 25941088
[TBL] [Abstract][Full Text] [Related]
39. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
